Ohno, Makoto
Miyakita, Yasuji
Takahashi, Masamichi
Igaki, Hiroshi
Matsushita, Yuko
Ichimura, Koichi
Narita, Yoshitaka
Article History
Received: 6 June 2019
Accepted: 2 October 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: All procedures performed in this study were in accordance with the ethical standards of the institutional and the 1964 Helsinki declaration and its later amendments. This study was approved by the internal review board of the National Cancer Center (2004–066 or 2007–086). Written informed consent was obtained from all individual participants.
: Not applicable.
: All the authors have nothing to disclose except Dr. Ichimura and Dr. Narita. Dr. Ichimura reports grants from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Daiichi Sankyo Co.Ltd., outside the submitted work. Dr. Narita reports grants from Japan Agency for Medical Research and Development, Chugai Pharmaceutical co., MSD, Eisai, Toshiba, SBI pharma, Glaxo, Abbive, Ono, Stella-pharma, Ohtuka, Meiji-seika, and Daiichi-Sankyo, outside the submitted work.